The questions a generics BD or procurement team actually runs during a sourcing cycle: who can supply this molecule, where is the country-pair (the lane) concentrated, what is the clearing price, is the supplier inspection-clean, where are we under-indexed. Sourced from customs clearance records, regulatory filings, and plant-level compliance data.
Find and qualify suppliers for a target molecule across API, FDF, CDMO, and intermediates. Registered-status filtering, plant inspection class, recent export volume, exclusivity windows. The first call when a buyer has a molecule and needs supply.
Quantify structural exposure on a buyer-side lane and surface registered second-source candidates. Herfindahl-Hirschman Index, top-3 exporter share, active-exporter count, capacity headroom, inspection-clean ranking.
Unit-price benchmarks from customs clearance records by molecule and country-pair (the lane), and by quarter. p25, median, p75 USD/kg distribution, pack-size pricing, YoY trend, aggressive-entry detection. Aggregated to protect counterparty identity.
The risk-quality filter applied to suppliers under consideration. FDA 483 observations, warning letters, plant inspection class, import alert tracker, environmental notices, sanctions exposure across the supplier graph.
Sourcing strategy across a portfolio of molecules. Spend allocation, safety-stock targets, demand forecasting from trade, reshoring opportunities, and supplier growth signals. Used to plan supply, not commercial entry.
Bring the three sourcing questions on your plate this week. We run them on PharmaDB in 30 minutes. You keep the answers.